How Can Epidemiology Help Optimize Anti-VEGF Therapy?

Epidemiology can play a crucial role in optimizing Anti-VEGF therapy by:

Identifying Population Disparities: Epidemiological studies can help identify disparities in access and outcomes, guiding targeted interventions.
Evaluating Effectiveness: Long-term studies can evaluate the real-world effectiveness of Anti-VEGF agents, informing clinical guidelines.
Monitoring Adverse Effects: Surveillance systems can monitor and report adverse effects, ensuring patient safety.
Guiding Policy Decisions: Data-driven insights can inform healthcare policies to improve access and affordability of Anti-VEGF therapies.